(KYMR) Kymera Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.972m USD | Total Return: 287.4% in 12m

Drug Discovery, Protein Degradation, Small Molecules, Clinical Trials
Total Rating 54
Safety 83
Buy Signal 0.16
Biotechnology
Industry Rotation: +3.6
Market Cap: 6.97B
Avg Turnover: 51.7M USD
ATR: 5.14%
Peers RS (IBD): 78.3
Risk 5d forecast
Volatility60.2%
Rel. Tail Risk-8.64%
Reward TTM
Sharpe Ratio1.76
Alpha210.99
Character TTM
Beta1.655
Beta Downside0.661
Drawdowns 3y
Max DD68.59%
CAGR/Max DD0.59
EPS (Earnings per Share) EPS (Earnings per Share) of KYMR over the last years for every Quarter: "2021-03": -0.29, "2021-06": -0.55, "2021-09": -0.56, "2021-12": -0.66, "2022-03": -0.71, "2022-06": -0.78, "2022-09": -0.79, "2022-12": -0.6, "2023-03": -0.7, "2023-06": -0.67, "2023-09": -0.9, "2023-12": -0.25, "2024-03": -0.62, "2024-06": -0.58, "2024-09": -0.82, "2024-12": -0.89, "2025-03": -0.82, "2025-06": -0.95, "2025-09": -0.94, "2025-12": -0.97, "2026-03": 0,
EPS CAGR: 43.80%
EPS Trend: 6.1%
Last SUE: 4.00
Qual. Beats: 1
Revenue Revenue of KYMR over the last years for every Quarter: 2021-03: 18.702, 2021-06: 18.519, 2021-09: 20.336, 2021-12: 15.275, 2022-03: 9.622, 2022-06: 11.514, 2022-09: 9.551, 2022-12: 16.139, 2023-03: 9.466, 2023-06: 16.513, 2023-09: 4.728, 2023-12: 47.885, 2024-03: 10.287, 2024-06: 25.65, 2024-09: 3.741, 2024-12: 7.394, 2025-03: 22.1, 2025-06: 11.476, 2025-09: 2.764, 2025-12: 2.86, 2026-03: null,
Rev. CAGR: -27.64%
Rev. Trend: -43.3%
Last SUE: -1.19
Qual. Beats: 0
Warnings

Interest Coverage Ratio -897.3 is critical

Altman Z'' -7.41 < 1.0 - financial distress zone

choppy

Tailwinds

No distinct edge detected

Description: KYMR Kymera Therapeutics

Kymera Therapeutics Inc. (NASDAQ: KYMR) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics. Their core technology utilizes the bodys natural protein degradation system to target disease-causing proteins. This approach is a novel method within drug discovery.

The companys pipeline includes an IRAK4 program in Phase II clinical trials for immunology-inflammation diseases like hidradenitis suppurativa and atopic dermatitis. They are also developing programs for STAT6 in allergic/atopic diseases and TYK2 for autoimmune and inflammatory conditions. The biopharmaceutical sector is characterized by lengthy and expensive drug development cycles.

Kymera has a strategic alliance with Sanofi S.A. for IRAK4 drug candidates, excluding oncology and immuno-oncology applications. This partnership provides external funding and validation for their research. Headquartered in Watertown, Massachusetts, the company was incorporated in 2015.

For more detailed financial and operational data, ValueRay offers in-depth company profiles.

Headlines to Watch Out For
  • Clinical trial results for KT-621 directly impact stock valuation
  • Sanofi collaboration milestones provide significant revenue streams
  • Regulatory approval timelines for drug candidates create volatility
  • Competition in protein degradation market affects future profitability
Piotroski VR‑10 (Strict) 1.0
Net Income: -311.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.13 > 0.02 and ΔFCF/TA 7.75 > 1.0
NWC/Revenue: 2.01k% < 20% (prev 940.1%; Δ 1.07k% < -1%)
CFO/TA -0.13 > 3% & CFO -232.9m > Net Income -311.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.47 > 1.5 & < 3
Outstanding Shares: last quarter (84.4m) vs 12m ago 5.50% < -2%
Gross Margin: 94.78% > 18% (prev 0.84%; Δ 9.39k% > 0.5%)
Asset Turnover: 2.88% > 50% (prev 4.81%; Δ -1.93% > 0%)
Interest Coverage Ratio: -897.3 > 6 (EBITDA TTM -302.4m / Interest Expense TTM 347k)
Altman Z'' -7.41
A: 0.45 (Total Current Assets 871.2m - Total Current Liabilities 83.2m) / Total Assets 1.74b
B: -0.61 (Retained Earnings -1.07b / Total Assets 1.74b)
C: -0.23 (EBIT TTM -311.4m / Avg Total Assets 1.36b)
D: -6.52 (Book Value of Equity -1.06b / Total Liabilities 163.1m)
Altman-Z'' Score: -7.41 = D
Beneish M
DSRI: none (Receivables none/947k, Revenue 39.2m/47.1m)
GMI: 0.89 (GM 94.78% / 84.34%)
AQI: 1.19 (AQ_t 0.45 / AQ_t-1 0.38)
SGI: 0.83 (Revenue 39.2m / 47.1m)
TATA: -0.05 (NI -311.4m - CFO -232.9m) / TA 1.74b)
Beneish M-Score: cannot calculate (missing components)
What is the price of KYMR shares? As of April 07, 2026, the stock is trading at USD 85.40 with a total of 690,900 shares traded.
Over the past week, the price has changed by +7.28%, over one month by +2.13%, over three months by +16.08% and over the past year by +287.41%.
Is KYMR a buy, sell or hold? Kymera Therapeutics has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy KYMR.
  • StrongBuy: 14
  • Buy: 3
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the KYMR price?
Analysts Target Price 119.1 39.5%
Kymera Therapeutics (KYMR) - Fundamental Data Overview as of 05 April 2026
P/S = 177.8139
P/B = 4.391
Revenue TTM = 39.2m USD
EBIT TTM = -311.4m USD
EBITDA TTM = -302.4m USD
Long Term Debt = 82.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 82.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -274.8m USD (from netDebt column, last quarter)
Enterprise Value = 6.21b USD (6.97b + Debt 82.3m - CCE 848.3m)
Interest Coverage Ratio = -897.3 (Ebit TTM -311.4m / Interest Expense TTM 347k)
EV/FCF = -26.48x (Enterprise Value 6.21b / FCF TTM -234.3m)
FCF Yield = -3.78% (FCF TTM -234.3m / Enterprise Value 6.21b)
 FCF Margin = -597.8% (FCF TTM -234.3m / Revenue TTM 39.2m)
 Net Margin = -794.4% (Net Income TTM -311.4m / Revenue TTM 39.2m)
 Gross Margin = 94.78% ((Revenue TTM 39.2m - Cost of Revenue TTM 2.05m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.56 (Enterprise Value 6.21b / Total Assets 1.74b)
Interest Expense / Debt = 0.08% (Interest Expense 69.0k / Debt 82.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -246.0m (EBIT -311.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.47 (Total Current Assets 871.2m / Total Current Liabilities 83.2m)
Debt / Equity = 0.05 (Debt 82.3m / totalStockholderEquity, last quarter 1.58b)
 Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -274.8m / EBITDA -302.4m)
 Debt / FCF = 1.17 (negative FCF - burning cash) (Net Debt -274.8m / FCF TTM -234.3m)
 Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = -22.89% (Net Income -311.4m / Total Assets 1.74b)
RoE = -29.08% (Net Income TTM -311.4m / Total Stockholder Equity 1.07b)
RoCE = -27.00% (EBIT -311.4m / Capital Employed (Equity 1.07b + L.T.Debt 82.3m))
 RoIC = -22.97% (negative operating profit) (NOPAT -246.0m / Invested Capital 1.07b)
 WACC = 11.67% (E(6.97b)/V(7.05b) * Re(11.81%) + D(82.3m)/V(7.05b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 11.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.34%
 [DCF] Fair Price = unknown (Cash Flow -234.3m)
 EPS Correlation: 6.14 | EPS CAGR: 43.80% | SUE: 4.0 | # QB: 1
Revenue Correlation: -43.31 | Revenue CAGR: -27.64% | SUE: -1.19 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.90 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=18
EPS current Year (2026-12-31): EPS=-3.60 | Chg7d=+0.005 | Chg30d=+0.012 | Revisions Net=+4 | Growth EPS=+2.5% | Growth Revenue=+1.0%
EPS next Year (2027-12-31): EPS=-4.01 | Chg7d=+0.009 | Chg30d=+0.058 | Revisions Net=+4 | Growth EPS=-11.4% | Growth Revenue=+3.4%
[Analyst] Revisions Ratio: +0.20 (6 Up / 4 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle